Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production

Transplantation

Volumn 73, Issue 11, 2002, Pages 1808-1817

  Jiang, Hongsi ^a   Wynn, Carmen ^a   Pan, Fan ^a   Ebbs, Aaron ^a   Erickson, Laurie M ^a   Kobayashi, Masakazu ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CYCLOSPORIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; RECEPTOR ANTIBODY; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; GRAFT REJECTION; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; MALE; MOLECULAR INTERACTION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RAT; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL;

EID: 0037096660     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200206150-00019     Document Type: Article

References (39)

1. Improved graft survival after renal transplantation in the United States, 1988 to 1996
2. Cyclosporine and tacrolimus (FK506): A comparison of efficacy and safety profiles
3. New immunosuppressive drugs: Mechanistic insights and potential therapeutic advance
4. FK506 and cyclosporine, molecular probes for studying intracellular signal transduction
5. Distinct patterns of cytokine gene suppression by the equivalent effective doses of cyclosporine and tacrolimus in rat heart allograft
6. Effect of FK506 versus cyclosporine on human natural and antibody-dependent cytotoxicity reaction in vitro
7. FK506 augments activation-induced programmed cell death of T lymphocytes in vivo
8. FK506 for liver, kidney, and pancreas transplantation
9. Phase II FK506 multicenter concentration control study: One year follow-up
10. Comparison of FK506 and cyclosporine-based immunosuppression in primary orthotopic liver transplantation
11. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection
12. Tacrolimus rescue therapy for renal allograft rejection: Five-year experience
13. Tacrolimus for primary treatment of steroid-resistant hepatic allograft rejection
14. Sequential cellular and molecular kinetics in acutely rejecting renal allografts in rats
15. Studies of the induction and maintenance of long-term graft acceptance by treatment with FK506 in heterotopic cardiac allotransplantation in rats
16. FK506 in clinical organ transplantation
17. FK506 conversion of renal allografts failing cyclosporine immunosuppression
18. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection: A report of the Tacrolimus Kidney Transplantation Rescue Study Group
19. Tacrolimus versus cyclosporin A: A comparative study on rat renal allograft survival
20. Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients
21. Improved technique of heart transplantation in rats
22. Cellular surface molecular and cytokine gene expression in rat heart allografts under optimal doses of cyclosporin and FK506
23. Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR
24. Biological properties of interleukin 10
25. Interleukin 10
26. Th1 and Th2 cell antigen receptors in experimental leishmaniasis
27. The expanding universe of T-cell subset: Th1, Th2 and more
28. Dendritic cells and prospects for transplantation tolerance
29. IL10, a novel growth cofactor for mature and immature T cells
30. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism
31. Stimulation of cytolytic activity by interleukin-10
32. Clinical application of molecular biology: A study of allograft rejection with polymerase chain reaction
33. Systemic administration of cellular interleukin-10 can exacerbate cardiac allograft rejection in mice
34. Systemic administration of anti-IL-10 antibody prolongs organ allograft survival in normal and presensitized recipients: Correlation with suppression of alloantibody production
35. Working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group
36. New insight into mechanisms of allograft rejection
37. Prolonged murine cardiac allograft acceptance
38. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice
39. Cytotoxic lymphocytes required granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells